Longitudinal changes in MoCA performances in patients with mild cognitive impairment and small vessel disease. Results from the VMCI-Tuscany Study.
Cerebral small vessel disease
Major neurocognitive disorder
Mild cognitive impairment
Montreal Cognitive Assessment
Journal
Cerebral circulation - cognition and behavior
ISSN: 2666-2450
Titre abrégé: Cereb Circ Cogn Behav
Pays: Netherlands
ID NLM: 101774849
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
12
2020
revised:
02
03
2021
accepted:
03
03
2021
entrez:
3
11
2022
pubmed:
21
3
2021
medline:
21
3
2021
Statut:
epublish
Résumé
The Montreal Cognitive Assessment (MoCA) is a cognitive screening test largely employed in vascular cognitive impairment, but there are no data about MoCA longitudinal changes in patients with cerebral small vessel disease (SVD). We aimed to describe changes in MoCA performance in patients with mild cognitive impairment (MCI) and SVD during a 2-year follow-up, and to evaluate their association with transition to major neurocognitive disorder (NCD). Within the prospective observational VMCI-Tuscany Study, patients with MCI and SVD underwent a comprehensive clinical, neuropsychological, and functional evaluation at baseline, and after 1 and 2 years. Among the 138 patients (mean age 74.4 ± 6.9 years; males: 57%) who completed the study follow-up, 44 (32%) received a major NCD diagnosis In our sample of MCI patients with SVD, longitudinal changes in MoCA performances were consistent with an expected more pronounced deterioration in patients who received a diagnosis of major NCD. MoCA sensitivity to change and predictive utility need to be further explored in VCI studies based on larger samples and longer follow-up periods.
Identifiants
pubmed: 36324712
doi: 10.1016/j.cccb.2021.100008
pii: S2666-2450(21)00005-2
pmc: PMC9616337
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100008Informations de copyright
© 2021 Published by Elsevier B.V.
Déclaration de conflit d'intérêts
None
Références
Neurol Sci. 2015 Feb;36(2):209-14
pubmed: 25139107
Behav Neurol. 2010;22(1-2):53-62
pubmed: 20543459
Med J Aust. 1999 Jan 18;170(2):81-5
pubmed: 10026690
Curr Opin Neurol. 2007 Aug;20(4):390-7
pubmed: 17620872
Mov Disord. 2012 Aug;27(9):1125-8
pubmed: 22692724
Int J Alzheimers Dis. 2012;2012:608013
pubmed: 22550606
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Dement Geriatr Cogn Disord. 2014;37(1-2):95-103
pubmed: 24107412
J Alzheimers Dis. 2018;62(1):409-416
pubmed: 29439344
Assessment. 2017 Sep;24(6):772-777
pubmed: 27318033
Aging Clin Exp Res. 2018 Aug;30(8):993-998
pubmed: 29188578
Neurol Sci. 2015 Apr;36(4):585-91
pubmed: 25380622
J Am Geriatr Soc. 2015 Sep;63(9):1874-9
pubmed: 26313522
Alzheimers Dement. 2016 Apr;12(4):407-18
pubmed: 26079418
Lancet Neurol. 2003 Feb;2(2):89-98
pubmed: 12849265
Dement Geriatr Cogn Dis Extra. 2018 Mar 29;8(1):104-116
pubmed: 29706987
Clin Neuropsychol. 2015;29(6):824-35
pubmed: 26373627
Lancet Neurol. 2010 Jul;9(7):689-701
pubmed: 20610345
J Alzheimers Dis. 2016 May 31;53(3):1107-14
pubmed: 27258421
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Neuroepidemiology. 2005;24(1-2):51-62
pubmed: 15459510
J Alzheimers Dis. 2015;43(4):1313-23
pubmed: 25147116
Neurol Sci. 2019 Apr;40(4):691-702
pubmed: 30637545